Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines.

T Feuth, R-L Patovirta, S Grierson, M Danilovits, P Viiklepp, H K Aaltonen, M Vauhkonen, L Pehme, T Vasankari
Author Information
  1. T Feuth: Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Division of Medicine, Department of Pulmonary Diseases, Turku University Hospital, Turku.
  2. R-L Patovirta: Department of Respiratory Medicine, Kuopio University Hospital, Kuopio.
  3. S Grierson: Finnish Lung Health Association (FILHA), Helsinki, Finland.
  4. M Danilovits: Lung Clinic of Tartu University Hospital, Tartu, Estonia.
  5. P Viiklepp: National Institute for Health Development, Tallinn, Estonia.
  6. H K Aaltonen: Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku.
  7. M Vauhkonen: Finnish Lung Health Association (FILHA), Helsinki, Finland.
  8. L Pehme: Lung Clinic of Tartu University Hospital, Tartu, Estonia.
  9. T Vasankari: Finnish Lung Health Association (FILHA), Helsinki, Finland.

Abstract

Multidrug-resistant TB (MDR-TB) is a growing problem in the effort to end the global TB epidemic. In 2019, the WHO adopted a new standardised regiment for MDR-TB, consisting of only oral medications. We estimated the impact of the new guidelines on the costs of TB treatment in Estonia and Finland. For both countries, the costs of the two most common new drug regimens were calculated, including drug costs, as well as care- and monitoring-related costs. In Turku, Finland, treatment costs with the old regimen were €178,714; this could either increase by 10% or decrease by 18%, depending on the duration of bedaquiline use (6 months vs. 20 months). In Estonia, treatment costs with the old regimen were €33,664, whereas the new regimens were associated with a 40% increase in overall costs. The 2019 WHO guidelines have led to significant changes in the costs of MDR-TB treatment in Finland and Estonia. These changes depend mostly on the drug regimen administered and on care-related practices, with important differences between countries and even within the same country due to local practices.

References

  1. Lancet Infect Dis. 2009 Mar;9(3):153-61 [PMID: 19246019]
  2. J Antimicrob Chemother. 2017 Apr 1;72(4):1243-1252 [PMID: 28073970]
  3. Respirology. 2018 Jul;23(7):656-673 [PMID: 29641838]
  4. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):677-689 [PMID: 30073886]
  5. Int J Tuberc Lung Dis. 2019 Jan 1;23(1):112-118 [PMID: 30674383]
  6. N Engl J Med. 2010 Sep 9;363(11):1050-8 [PMID: 20825317]
  7. Infect Dis Rep. 2016 Jun 24;8(2):6569 [PMID: 27403268]
  8. Pharmacoeconomics. 2015 Sep;33(9):939-55 [PMID: 25939501]
  9. Expert Rev Anti Infect Ther. 2020 May;18(5):475-483 [PMID: 32186925]
  10. BMJ Open. 2020 Oct 10;10(10):e036599 [PMID: 33039989]
  11. Int J Tuberc Lung Dis. 2017 Apr 1;21(4):477-478 [PMID: 28284273]
  12. Emerg Infect Dis. 2014 May;20(5):812-21 [PMID: 24751166]
  13. Pharmacoeconomics. 2012 Jan;30(1):63-80 [PMID: 22070215]
  14. Clin Respir J. 2012 Jan;6(1):35-9 [PMID: 21554562]
  15. Trop Med Int Health. 2013 Jan;18(1):109-16 [PMID: 23170876]
  16. Int J Tuberc Lung Dis. 2016 Apr;20(4):435-41 [PMID: 26970150]

MeSH Term

Antitubercular Agents
Estonia
Finland
Humans
Tuberculosis, Multidrug-Resistant
World Health Organization

Chemicals

Antitubercular Agents

Word Cloud

Created with Highcharts 10.0.0coststreatmentTBnewEstoniaFinlandMDR-TB2019WHOguidelinesdrugregimencountriesregimensoldincreasemonthschangespracticesMultidrug-resistantgrowingproblemeffortendglobalepidemicadoptedstandardisedregimentconsistingoralmedicationsestimatedimpacttwocommoncalculatedincludingwellcare-monitoring-relatedTurku€178714either10%decrease18%dependingdurationbedaquilineuse6vs20€33664whereasassociated40%overallledsignificantdependmostlyadministeredcare-relatedimportantdifferencesevenwithincountryduelocalCostsmultidrug-resistantaffected

Similar Articles

Cited By